Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PENTOXIFYLLINE

All products: not a benefit

Trental · DIN 02221977 · 400mg · extended release tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2013-03-01 — choose a marketed DIN from the same-category list.Discontinued 2013-03-01 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2013-03-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2013-03-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 76, 529
Reason for Use code 76 For the treatment of patients with critical limb ischemia (with arterial ulcers, gangrene and/or rest pain) and documented arterial vascular disease. Coverage limit: Limited Use form must specify if arterial ulcers, gangrene and/or rest pain are present. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 529 For the treatment of patients with venous ulcers lasting, or expected to last, more than 8 weeks. Treatment should be discontinued after 3 months if there is no indication of objective benefit. The duration of therapy with pentoxifylline should not exceed 12 months. Coverage limit: Pentoxifylline should be used in combination with compression therapy. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Trental · DIN 02221977 Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-07 Health Canada: Cancelled post market since 2013-03-01 · brand TRENTAL · ATC C04AD03 PENTOXIFYLLINE · form Tablet (extended-release) · route Oral · ingredients PENTOXIFYLLINE 400 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Trental: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43321 · Verify on the e-Formulary ↗ (DIN 02221977)

Source record
DIN 02221977: Trental Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 202400001; group id 271; item number 0561; lccId 00049; manufacturer id SAV Source form: SR Tab; strength: 400mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02221977 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43321
Interchangeable products
Apo-Pentoxifylline SR · DIN 02230090 · $0.7238 Jamp Pentoxifylline SR · DIN 02543087 · $0.7238
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02221977
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2013-03-01 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (20:24 Hemorrheologic Agents) and how they are covered
No products matched this class search: “20:24”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 20:04 Antianemia Drugs, 20:12 Coagulants and Anti-Coagulants, 20:16 Hematopoietic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS APO-PENTOXIFYLLINE SR (pentoxifylline) is indicated for: • symptomatic treatment of patients with chronic occlusive peripheral vascular disorders of the extremities. In such patients pentoxifylline may give relief of signs and symptoms of impaired blood flow, such as intermittent claudication or trophic ulcers. 1.1 Pediatrics Pediatrics (<18 years): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of APO-PENTOXIFYLLINE SR in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 4 DOSAGE AND ADMINISTRATION. In general, dose selection for a geriatric patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. https://pdf.hres.ca/dpd_pm/00080904.PDF PM date: JAN 14, 1997 Source product: APO-PENTOXIFYLLINE SR; DIN 02230090; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Trental: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026